Oxygenta Pharmaceutical Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, sales was INR 149.5 million compared to INR 375.19 million a year ago. Revenue was INR 149.5 million compared to INR 375.19 million a year ago. Net loss was INR 40.3 million compared to INR 0.894 million a year ago. Basic loss per share from continuing operations was INR 2.84 compared to INR 0.06 a year ago. Diluted loss per share from continuing operations was INR 2.84 compared to INR 0.06 a year ago.